Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

Cancer research - 1 Jul 2010

Yang Hong, Higgins Brian, Kolinsky Kenneth, Packman Kathryn, Go Zenaida, Iyer Raman, Kolis Stanley, Zhao Sylvia, Lee Richard, Grippo Joseph F, Schostack Kathleen, Simcox Mary Ellen, Heimbrook David, Bollag Gideon, Su Fei

Abstract excerpt

The BRAF(V600E) mutation is common in several human cancers, especially melanoma. RG7204 (PLX4032) is a small-molecule inhibitor of BRAF(V600E) kinase activity that is in phase II and phase III clinical testing. Here, we report a preclinical characterization of the antitumor activity of RG7204 us...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Growth Processes
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to MAP Kinase Kinase Kinases

Share to Mice, Nude

Share to Sulfonamides

Share to Vemurafenib

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 20551065
DOI: 10.1158/0008-5472.CAN-10-0646

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20551065-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.PMID 20551065Read ↗

Targeting BRAF in advanced melanoma: a first step toward manageable disease.Semantic proximity Read ↗

Inhibition of mutated, activated BRAF in metastatic melanoma.Semantic proximity Read ↗

Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant MelanomaSemantic proximity Read ↗

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.Semantic proximity Read ↗

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.Semantic proximity Read ↗

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.Semantic proximity Read ↗

EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.Semantic proximity Read ↗

The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.Semantic proximity Read ↗

Multiple murine BRaf<sup>V600E</sup> melanoma cell lines with sensitivity to PLX4032Semantic proximity Read ↗

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.Semantic proximity Read ↗

Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.Semantic proximity Read ↗

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.